Dedicated MR vendor Fonar is in compliance with the Nasdaq stock exchange, ending concerns that the company would be delisted.
Fonar enters Nasdaq good graces
Dedicated MR vendor Fonar is in compliance with the Nasdaq stock exchange, ending concerns that the company would be delisted. At issue was whether Fonar satisfied Nasdaq Listing Rule 5550(b)(3), which requires companies on the exchange to have a minimum $500,000 of net income from continuing operations in the latest fiscal year. Fonar’s most recent Form 10-K, filed Oct. 5, showed net income from continuing operations of $1.1 million for the fiscal year ended June 30, 2009.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.